Trial 0C-23-10


A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Biological Response Modifier
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jacob Thomas, M.D.
Other Trial Staff:  Yan Ning, D.M., Lorraine Martinez, Coordinator, Nicole Jensen, Coordinator, Mary Ordaz, D.M., Xiomara Menendez, Coordinator, Jessica Levano, Coordinator, Arthur Alvarez, D.M., Khatchik Karakozian, D.M., Niranjan Bhatt, D.M., Negeen Izadian, Coordinator, Clara Karam, D.M., Bomi Choi, Coordinator, Brianna Olea, Coordinator, Marc Cruz, D.M., Stephanie Kim, Coordinator, Maura Fernandez, D.M., Teshia Bustos, Coordinator, Alexandra Artura, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.